title: Modulating the vascular response to limb ischemia: angiogenic and cell therapies.
abstract: The age-adjusted prevalence of peripheral arterial disease in the US population has been estimated to approach 12%. The clinical consequences of occlusive peripheral arterial disease include pain on walking (claudication), pain at rest, and loss of tissue integrity in the distal limbs; the latter may ultimately lead to amputation of a portion of the lower extremity. Surgical bypass techniques and percutaneous catheter-based interventions may successfully reperfuse the limbs of certain patients with peripheral arterial disease. In many patients, however, the anatomic extent and distribution of arterial occlusion is too severe to permit relief of pain and healing of ischemic ulcers. No effective medical therapy is available for the treatment of such patients, for many of whom amputation represents the only hope for alleviation of symptoms. The ultimate failure of medical treatment and procedural revascularization in significant numbers of patients has led to attempts to develop alternative therapies for ischemic disease. These strategies include administration of angiogenic cytokines, either as recombinant protein or as gene therapy, and more recently, to investigations of stem/progenitor cell therapy. The purpose of this review is to provide an outline of the preclinical basis for angiogenic and stem cell therapies, review the clinical research that has been done, summarize the lessons learned, identify gaps in knowledge, and suggest a course toward successfully addressing an unmet medical need in a large and growing patient population.
authors.affiliation: From the Department of Cardiovascular Sciences, Houston Methodist Research Institute, TX (J.P.C.); and NeoStem Inc, New York, NY (D.W.L.). jpcooke@houstonmethodist.org dlosordo@neostem.com.
authors.forename: John P
authors.initials: JP
authors.lastname: Cooke
authors.affiliation: From the Department of Cardiovascular Sciences, Houston Methodist Research Institute, TX (J.P.C.); and NeoStem Inc, New York, NY (D.W.L.). jpcooke@houstonmethodist.org dlosordo@neostem.com.
authors.forename: Douglas W
authors.initials: DW
authors.lastname: Losordo
mesh_terms: D017690:Cell Transplantation / Q000379:methods*; D005346:Fibroblast Growth Factors / Q000235:genetics / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007511:Ischemia / Q000235:genetics / Q000601:surgery / Q000628:therapy*; D035002:Lower Extremity / Q000098:blood supply*; D058729:Peripheral Arterial Disease / Q000235:genetics / Q000601:surgery / Q000628:therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors
keywords: angiogenesis; genetic therapy; microvessels; progenitor cell; stem cells; vasculogenesis